DeePathology.ai
AI-based Pathology Decision-support Platform
Company Overview
Snapshot
Founded in September 2018 by Chen Sagiv, Nizan Sagiv, and Jacob Gildenblat, DeePathology.ai operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its AI-based pathology decision-support platform. In December 2019, DeePathology.ai announced a technical partnership and solution integration with Inspirata, signaling strategic market entry and collaboration.
Business overview
DeePathology.ai develops an AI-based decision-support system for digital pathology, leveraging proprietary artificial intelligence technology to implement solutions for the digital pathology market. The company's core technology enables rapid and accurate AI applications for problems such as helicobacter pylori detection, plaque detection, and lymphocyte detection in biopsies. DeePathology.ai offers cell-detection and tissue-segmentation solutions, empowering pathologists and researchers to develop AI-based tools without requiring deep AI expertise. Its solutions are currently integrated into workflows in various European locations, serving the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Decision Support, with a focus on healthcare providers in North America, Europe, and Asia.
Strategic signal
In December 2019, DeePathology.ai announced a technical partnership and solution integration with Inspirata. This collaboration is a significant signal, demonstrating the company's ability to form strategic alliances and integrate its AI-based pathology solutions into existing clinical workflows, validating its technology and market readiness for broader adoption within the digital pathology industry.
Log in to access full profile ›Company Intelligence Q&A
- What is DeePathology.ai's primary focus?
- DeePathology.ai focuses on developing an AI-based decision-support system for digital pathology, utilizing artificial intelligence technology to provide solutions for problems such as helicobacter pylori detection, plaque detection, and lymphocyte detection.
- When was DeePathology.ai founded?
- DeePathology.ai was founded in September 2018 by Chen Sagiv, Nizan Sagiv, and Jacob Gildenblat.
- What significant partnership did DeePathology.ai announce?
- In December 2019, DeePathology.ai announced a technical partnership and solution integration with Inspirata.
- What markets does DeePathology.ai target?
- DeePathology.ai targets geomarkets in North America, Europe, and Asia, with solutions already in use in various locations in Europe.
- What kind of solutions does DeePathology.ai offer?
- DeePathology.ai offers cell-detection and tissue-segmentation solutions that enable pathologists and researchers to develop their own AI-based solutions in their labs without needing to be AI experts.